Flowvium

Unternehmensvergleich

Seitenweise Analyse von Lieferkettenposition, institutionellen Signalen und Nachrichten-Lückenwerten.

VS

Marktkapitalisierung

MegavsMega

Ketten-Rolle

leadervsleader

Lückenwert

20vs38

IB-Aktivität

88vs84

Umsatzmix-Vergleich

LLY
NVO
LLY

Eli Lilly and Company

LLY · pharma-biotech

leaderMega ($100B+)
Vollständiges Profil

Über

Eli Lilly is the world's most valuable pharmaceutical company, propelled by the blockbuster GLP-1 receptor agonist tirzepatide (Mounjaro/Zepbound) for diabetes and obesity. Its Alzheimer's antibody donanemab and strong oncology pipeline give it one of the most promising drug portfolios in the industry.

Gegründet

1876

Mitarbeiter

43,000+

Hauptsitz

Indianapolis, Indiana, USA

Umsatz

$52.8B

Diabetes & Obesity52%
Oncology18%
Immunology12%
Neuroscience10%
Other (Insulin Legacy)8%

News-Gap-Signal

Lückenwert (Stille = Signal)20
IB-Aktivitätswert88
Medienabdeckungswert75

IB-Aktivität: HIGH

Institutionelle Signale

accumulating$1.8B

BlackRock

2024-08-13

accumulating$672M

BlackRock

2024-08-13

accumulating$676M

BlackRock

2024-08-13

Schlüsselbeziehungen

NVO· Novo Nordisk
competitor
PFE· Pfizer Inc.
competitor
REGN· Regeneron Pharmaceuticals
competitor
MRNA· Moderna, Inc.
partner
NVO

Novo Nordisk

NVO · pharma-biotech

leaderMega ($100B+)
Vollständiges Profil

Über

Novo Nordisk is the global leader in diabetes care and has become a GLP-1 giant with Ozempic and Wegovy. The obesity-drug revolution has made it Europe's most valuable company. Its near-monopoly on injectable semaglutide positions it at the center of the $100B+ weight-loss drug market.

Gegründet

1923

Mitarbeiter

64,000+

Hauptsitz

Bagsvaerd, Denmark

Umsatz

$42.6B

GLP-1 Diabetes (Ozempic, Rybelsus)42%
Obesity (Wegovy)25%
Insulin20%
Rare Disease & Other13%

News-Gap-Signal

Lückenwert (Stille = Signal)38
IB-Aktivitätswert84
Medienabdeckungswert62

IB-Aktivität: HIGH

Institutionelle Signale

reducing$163K

BlackRock

2024-08-13

accumulating$200M

BlackRock

2024-08-13

reducing$23M

BlackRock

2024-08-13

Schlüsselbeziehungen

LLY· Eli Lilly and Company
competitor
PFE· Pfizer Inc.
competitor